DE60318081D1 - Verwendung von brimonidine zur behandlung von dementia und morbus parkinson - Google Patents

Verwendung von brimonidine zur behandlung von dementia und morbus parkinson

Info

Publication number
DE60318081D1
DE60318081D1 DE60318081T DE60318081T DE60318081D1 DE 60318081 D1 DE60318081 D1 DE 60318081D1 DE 60318081 T DE60318081 T DE 60318081T DE 60318081 T DE60318081 T DE 60318081T DE 60318081 D1 DE60318081 D1 DE 60318081D1
Authority
DE
Germany
Prior art keywords
brimonidine
dementia
treatment
morbus parkinson
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318081T
Other languages
English (en)
Other versions
DE60318081T2 (de
Inventor
William G Tatton
Larry A Wheeler
Daniel W Gil
John E Donello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE60318081D1 publication Critical patent/DE60318081D1/de
Application granted granted Critical
Publication of DE60318081T2 publication Critical patent/DE60318081T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60318081T 2002-10-08 2003-10-07 Verwendung von brimonidine zur behandlung von dementia und morbus parkinson Expired - Lifetime DE60318081T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41703102P 2002-10-08 2002-10-08
US417031P 2002-10-08
PCT/US2003/031842 WO2004032934A1 (en) 2002-10-08 2003-10-07 Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons

Publications (2)

Publication Number Publication Date
DE60318081D1 true DE60318081D1 (de) 2008-01-24
DE60318081T2 DE60318081T2 (de) 2008-11-06

Family

ID=32093952

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318081T Expired - Lifetime DE60318081T2 (de) 2002-10-08 2003-10-07 Verwendung von brimonidine zur behandlung von dementia und morbus parkinson

Country Status (20)

Country Link
US (1) US20040116436A1 (de)
EP (1) EP1549314B1 (de)
JP (1) JP2006504741A (de)
KR (1) KR20050056235A (de)
CN (1) CN100370988C (de)
AT (1) ATE380551T1 (de)
AU (2) AU2003279874A1 (de)
BR (1) BR0314541A (de)
CA (1) CA2501348A1 (de)
DE (1) DE60318081T2 (de)
ES (1) ES2297233T3 (de)
HK (1) HK1080408B (de)
IL (1) IL167848A (de)
MX (1) MXPA05003665A (de)
NO (1) NO20051664L (de)
NZ (1) NZ539329A (de)
PL (1) PL376347A1 (de)
RU (1) RU2332218C2 (de)
WO (1) WO2004032934A1 (de)
ZA (1) ZA200502745B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
DE102009043750A1 (de) * 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
US10022341B2 (en) * 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота
EP3491391A4 (de) * 2016-08-01 2020-04-29 Cognoptix, Inc. System und verfahren zur erkennung von tau-protein in augengewebe

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
RU2176145C2 (ru) * 1995-05-26 2001-11-27 Пфайзер Инк. Синергическое лечение паркинсонизма
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
IL136388A0 (en) * 1997-12-04 2001-06-14 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components

Also Published As

Publication number Publication date
ES2297233T3 (es) 2008-05-01
ATE380551T1 (de) 2007-12-15
NO20051664L (no) 2005-05-31
RU2005114505A (ru) 2005-10-27
AU2003279874A1 (en) 2004-05-04
NZ539329A (en) 2007-11-30
WO2004032934A1 (en) 2004-04-22
DE60318081T2 (de) 2008-11-06
HK1080408A1 (en) 2006-04-28
BR0314541A (pt) 2005-07-26
CN100370988C (zh) 2008-02-27
MXPA05003665A (es) 2005-06-08
ZA200502745B (en) 2006-07-26
IL167848A (en) 2010-11-30
CN1703222A (zh) 2005-11-30
US20040116436A1 (en) 2004-06-17
AU2010200730A1 (en) 2010-03-18
HK1080408B (zh) 2008-08-08
KR20050056235A (ko) 2005-06-14
EP1549314B1 (de) 2007-12-12
CA2501348A1 (en) 2004-04-22
PL376347A1 (en) 2005-12-27
EP1549314A1 (de) 2005-07-06
JP2006504741A (ja) 2006-02-09
RU2332218C2 (ru) 2008-08-27

Similar Documents

Publication Publication Date Title
DE60132777D1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60010702D1 (de) Behandlung von titanerz zur herstellung von titandioxidpigmenten
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE325808T1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE427928T1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
NO20051664L (no) Behandling av demens og Parkinsons sykdom
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE602005017762D1 (de) Methode zur behandlung trockener augen und uveitis
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE328887T1 (de) Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE60327335D1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson

Legal Events

Date Code Title Description
8364 No opposition during term of opposition